Credit Suisse lowered the firm’s price target on Fulgent Genetics to $45 from $50 following quarterly results. The firm keeps an Outperform rating on the shares as it believes the company is poised to gain share in the genetic and oncology testing markets due to synergies from its recent acquisitions and disruptions at competitors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FLGT:
- Fulgent Genetics launches new Beacon787 expanded carrier screening panel
- Raymond James Sees ‘Multiple Expansion’ to Drive Stock Market Returns — Here Are 2 Stocks to Play That Bullish Sentiment
Questions or Comments about the article? Write to editor@tipranks.com